Cardiac Imaging & Market Watch

One Heartbeat, Almost No Radiation: FLASH Photon-Counting CCTA Comes of Age for Young, Low-Risk Patients

Clinical synthesis with an investor lens for physician-investors in cardiovascular imaging

A new prospective registry presented at the 2026 Society of Cardiovascular Computed Tomography meeting suggests that young, low-risk patients referred for coronary CT angiography can be scanned with almost no radiation at all.

Using a single-heartbeat, high-pitch acquisition technique called FLASH on a fourth-generation photon-counting CT scanner, investigators achieved a median effective dose of just 0.82 mSv.

That is lower than the radiation from a routine coronary calcium score, long considered the lowest-dose cardiac CT test available.

For physicians who order or perform cardiac CT, this data point reframes what a "low-radiation" coronary study can look like in practice.

Figure 1. Approximate effective radiation doses across common cardiac imaging protocols, shown for orientation rather than head-to-head comparison.

What the Registry Showed

Investigators enrolled 70 patients with no known coronary disease referred for CCTA, with a mean age of 36 and 41% women.

All scans used the FLASH protocol, a prospective high-pitch helical acquisition that captures the entire heart in a single cardiac cycle rather than over several heartbeats.

Scanning was performed on a fourth-generation dual-source photon-counting CT scanner (marketed as NAEOTOM Alpha).

Mean body mass index was 26.5 kg/m² and mean heart rate was 58 beats per minute, reflecting careful patient selection.

More than half the cohort (59%) had dyslipidemia, and just over half (51%) had a family history of premature coronary disease.

Effective radiation dose fell below 1 mSv in 70% of patients, with a median of 0.82 mSv for the full cohort.

Image quality was rated excellent in 51% and good in 27%, while 9% of scans (six patients) were nondiagnostic and required a repeat study.

On CAD-RADS scoring, 81% of patients were classified as CAD-RADS 0 and 16% as CAD-RADS 1, meaning 97% had no or minimal disease.

One patient was scored CAD-RADS 2, and one was scored CAD-RADS 4A, a finding that was subsequently confirmed by invasive coronary angiography.

Figure 2. CAD-RADS classification among 70 patients scanned with the FLASH photon-counting protocol.

Table 1. FLASH Photon-Counting CCTA Registry at a Glance

Parameter	Result
Cohort size	70 patients
Mean age / % women	36 years / 41%
Mean BMI	26.5 kg/m²
Mean heart rate	58 bpm
Median effective dose	0.82 mSv
Dose <1 mSv	70% of patients
Nondiagnostic scans	9% (6 patients)
CAD-RADS 0 or 1	97% of patients

Why a Single Heartbeat Matters

FLASH acquisition is available on most modern CT scanners, but many imagers have been reluctant to use it because it provides only one cardiac phase rather than the multiphase buffer of conventional protocols.

That single-phase design behaves like a bet on the patient's physiology: a steady, slow heart rate produces a crisp image, while an irregular or fast rhythm risks a nondiagnostic study.

The registry's authors framed this trade-off directly, noting that even a failed FLASH scan carries only a small radiation penalty before falling back to a conventional protocol.

Photon-counting detectors add a second, complementary advance by directly registering individual X-ray photons rather than integrating their combined energy.

This design reduces electronic background noise, sharpens spatial resolution, and lessens blooming artifact around calcified plaque and stents, all of which support confident low-dose imaging.

The combination of ultrafast single-beat acquisition with photon-counting detection is what allowed this cohort's median dose to undercut a standard calcium score.

Heart rate control was central to success, and the study team relied on beta-blockers to bring resting heart rates down before scanning.

Patients with a resting heart rate above 70 beats per minute were switched to a conventional prospective protocol rather than attempting FLASH.

Table 2. Common Beta-Blockers Used for Pre-CCTA Heart Rate Control

Generic name	Common brand	Route	Approx. cash price (GoodRx)
Metoprolol tartrate	Lopressor	Oral / IV	~$7–17 per 30-day oral supply
Metoprolol succinate	Toprol XL	Oral, once daily	~$12–20 per 30-day supply

Clinical Vignette

A 34-year-old nonsmoking marketing executive with a strong family history of premature coronary disease and borderline dyslipidemia presents with atypical chest tightness during a stressful workweek.

Her resting heart rate is 56 beats per minute and her calculated pretest probability of obstructive disease is low.

Rather than defaulting to a standard-dose CCTA protocol, her imaging team selects a single-heartbeat FLASH acquisition on their photon-counting scanner after a low dose of oral metoprolol.

The study is read as CAD-RADS 0, delivered at a dose lower than her prior coronary calcium score, and she is reassured and discharged with standard preventive counseling.

Practical Considerations Before Adopting FLASH

Both patient body size and heart rate variability determine candidacy, and sinus arrhythmias common in younger patients can still be accommodated with careful protocolling.

A resting heart rate that is too high or too variable is the most common reason to abandon FLASH in favor of a conventional prospective, multiphase acquisition.

Radiology and cardiology teams, along with their technologists, need shared buy-in before rolling out a low-dose FLASH pathway, since patient selection drives success.

The authors specifically plan to prioritize this protocol for younger patients with chest pain who need coronary anatomy clarified, including evaluation for anomalous coronary arteries.

Broader adoption also intersects with a decade-long trend of falling CCTA radiation doses as scanner technology and protocols have matured industry-wide.

The Business of Photon-Counting CT

The scanner used in this registry is manufactured by Siemens Healthineers AG, whose Imaging division is the commercial home for its photon-counting CT platform.

Siemens Healthineers trades in the US as an OTC ADR and on its primary Frankfurt listing, giving investors two ways to track the same underlying business.

Photon-counting CT has been repeatedly highlighted by company leadership as a growth driver within the broader Imaging segment.

Table 3. Siemens Healthineers AG — Company Snapshot

Metric	Value
Ticker (US OTC)	SMMNY
Primary listing	Frankfurt Stock Exchange (SHL)
Recent share price (OTC)	~$20.26 (as of Jun 9, 2026)
Relevant segment	Imaging (CT, MRI, X-ray, ultrasound)
Analyst consensus / 12-mo target	Not published on StockAnalysis.com for the OTC listing at time of writing

Because stock prices and analyst estimates move continuously, treat the figures above as a point-in-time snapshot rather than a current quote.

Bottom Line

In carefully selected young, low-risk patients with controlled heart rates, single-heartbeat FLASH acquisition on a photon-counting CT scanner can deliver diagnostic-quality coronary imaging at a radiation dose below that of a standard calcium score.

Success depends heavily on patient selection, heart rate control, and institutional readiness rather than the technology alone.

For physician-investors, the data reinforce photon-counting CT as a durable growth narrative for imaging equipment manufacturers, independent of any single stock's near-term price action.

Want this turned into a short video script, a social media summary, or a patient-facing handout on low-radiation heart CT? Just ask.

References

1. TCTMD conference coverage of SCCT 2026, Chula Vista, CA, July 9–12, 2026.
2. Society of Cardiovascular Computed Tomography news release on CAD-RADS 2.0.
3. FDA patient guidance on radiation risks from CT.
4. StockAnalysis.com company profile for Siemens Healthineers AG.
5. GoodRx pricing information for metoprolol.

Physician education disclaimer: This article is intended for physician education and reflects a synthesis of publicly available conference and industry data as of the date of writing; it is not a substitute for full peer-reviewed publication, institutional protocols, or individualized clinical judgment.

Financial disclaimer: Stock tickers, prices, and company information are provided for general educational context only, reflect a single point in time, and do not constitute investment advice or a recommendation to buy or sell any security.